Boundless Bio, Inc. (BOLD) Revenue History
Annual and quarterly revenue from 2016 to present
BOLD Revenue Over Time (2016–2025)
BOLD Revenue Growth History
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
BOLD Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 20, 2026, Boundless Bio, Inc. (BOLD) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
BOLD's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including MGNX (+3.1% YoY), TPVG, and KYMR (-12.6% YoY). Compare BOLD vs MGNX →
BOLD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BOLDCurrent | $0 | - | - | - | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% | |
 TPVG | $97M | - | - | 77.9% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% |
BOLD Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-1,251,000 | - | $-63,552,000 | - |
| 2024 | $0 | - | $-1,086,000 | - | $-73,267,000 | - |
| 2023 | $0 | - | $0 | - | $-54,796,000 | - |
| 2022 | $0 | - | $0 | - | $-46,469,000 | - |
| 2021 | $0 | - | $0 | - | $-25,301,000 | - |
| 2018 | $0 | - | $0 | - | $-134,372,000 | - |
| 2017 | $0 | - | $0 | - | $-93,177,000 | - |
| 2016 | $0 | - | $0 | - | $-60,046,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BOLD — Frequently Asked Questions
Quick answers to the most common questions about buying BOLD stock.
Is BOLD's revenue growth accelerating or slowing?
BOLD TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is BOLD's revenue history from 2016 to 2026?
Boundless Bio, Inc. (BOLD) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BOLD's long-term revenue growth rate (CAGR)?
Boundless Bio, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BOLD.
Why does BOLD's quarterly revenue fluctuate?
BOLD quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Boundless Bio, Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is BOLD's revenue distributed by segment?
BOLD reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BOLD's revenue compare to industry peers?
Boundless Bio, Inc. (BOLD) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.